+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Letermovir Drugs Market by Indication (Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation), Route of Administration (Intravenous, Oral), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Letermovir Drugs Market by Indication (Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation), Route of Administration (Intravenous, Oral), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Letermovir Drugs Market by Indication (Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation), Route of Administration (Intravenous, Oral), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6132423
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Cytomegalovirus (CMV) poses a significant threat to transplant recipients, as immune suppression creates fertile ground for viral reactivation and systemic complications. For decades, clinicians have relied on conventional antiviral regimens that often carry toxicity concerns and practical limitations in long-term prophylaxis. In response, the introduction of letermovir has marked a paradigm shift, offering a targeted mechanism of action against the CMV terminase enzyme and demonstrating a favorable safety profile compared to nucleoside analogues.

This introduction outlines the foundational context for understanding letermovir’s unique position in CMV prophylaxis. It explores the unmet clinical needs in hematopoietic stem cell and solid organ transplant settings, highlights evolving patient management priorities, and frames key developments that inform our comprehensive analysis. By setting the stage for deeper exploration, this section establishes the relevance of technological advances, regulatory considerations, and market dynamics that will be examined in subsequent chapters.

Examining Key Technological Advances and Clinical Practice Shifts Shaping Letermovir Adoption and Administration across Transplantation Settings

Over the past several years, a convergence of scientific breakthroughs and practice-driven reforms has accelerated the integration of letermovir into standard care protocols. Advances in formulation science have enabled seamless transition from intravenous infusion in inpatient units to oral administration in outpatient and home-based settings, reducing logistical complexity and enhancing patient adherence. Concurrently, the publication of real-world evidence has reinforced safety and efficacy outcomes, encouraging transplant centers to revise institutional guidelines.

Moreover, digital health platforms have facilitated remote monitoring of viral load, enabling clinicians to personalize prophylactic regimens and intervene earlier when viral reactivation is detected. Interdisciplinary collaboration among infectious disease specialists, pharmacists, and nursing teams has refined patient pathways, ensuring timely initiation of letermovir and consistent follow-up. As these transformative shifts unfold, physicians and health systems are poised to harness the full potential of targeted antiviral prophylaxis.

Analyzing the Multifaceted Implications of Emerging United States Tariff Policies on Availability and Cost Structures for Letermovir Therapeutics

In early 2025, the United States implemented revised tariff measures on a range of pharmaceutical ingredients and finished dosage forms, triggering notable repercussions throughout the supply chain. Manufacturing partners faced increased input costs for active pharmaceutical ingredients, while domestic producers encountered new pricing pressures under import tariff obligations. These changes have directly affected procurement budgets and prompted renegotiation of supply agreements across the letermovir value chain.

Hospitals and specialty pharmacies have responded by optimizing inventory turnover and exploring alternative sourcing strategies to maintain uninterrupted access to letermovir. At the same time, payers and reimbursement authorities are scrutinizing the impact of tariff-driven cost fluctuations on formulary placements and reimbursement tiers. Moving forward, stakeholders will need to balance cost containment imperatives with the imperative to sustain timely prophylaxis for vulnerable transplant populations, forging strategic alliances with suppliers to mitigate tariff-related volatility.

Unveiling Critical Segmentation Insights by Indication Route of Administration Distribution Channel and End User Influencing Letermovir Utilization Patterns

Segmentation by clinical indication reveals distinct utilization patterns within the transplant landscape. In hematopoietic stem cell transplantation, allogeneic recipients demonstrate heightened reliance on prophylactic antiviral agents due to elevated graft-versus-host disease risk, whereas autologous patients typically follow shorter prophylaxis courses aligned with rapid immune reconstitution. In solid organ transplantation, kidney recipients present a sustained prophylactic need driven by long-term immunosuppression protocols, while liver recipients benefit from tailored regimens attuned to hepatic clearance profiles.

The choice of administration route significantly shapes clinical workflow. Intravenous delivery remains essential during initial hospitalization when gastrointestinal absorption may be compromised, but clinicians increasingly transition stable patients to oral therapy to facilitate early discharge and reduce health care resource utilization. Distribution channels further influence access paradigms. Hospital pharmacies ensure direct supply for inpatient care, online pharmacies have expanded home delivery capabilities, and retail pharmacies serve as critical touchpoints for outpatient prescription fulfillment.

End users encompass ambulatory care centers, where streamlined outpatient infusion services are emerging; hospital inpatient units, which manage acute post-transplant prophylaxis; and specialty clinics that coordinate long-term follow-up. Understanding these interwoven segmentation dimensions is vital for strategizing market engagement and ensuring that letermovir reaches diverse patient cohorts through optimal channels.

Evaluating Regional Landscape Dynamics in the Americas Europe Middle East Africa and Asia Pacific Shaping Letermovir Market Penetration

The Americas lead in letermovir penetration, driven by established reimbursement frameworks, advanced transplant infrastructures, and early inclusion in clinical guidelines. High transplantation volumes in North America have fostered rapid uptake, while pockets of demand in Latin America are beginning to emerge as health systems invest in post-transplant prophylaxis capabilities. Despite this momentum, regional payers are closely monitoring cost implications of prolonged prophylaxis.

In Europe, Middle East & Africa, access varies considerably across countries. Western European markets have adopted letermovir rapidly, backed by robust pharmacovigilance networks and supportive regulatory pathways. In contrast, emerging markets in Eastern Europe and parts of the Middle East navigate budgetary constraints and prioritize generics, creating heterogeneous uptake profiles. African regions face infrastructure and distribution challenges, underscoring the need for innovative supply-chain solutions.

Asia-Pacific presents a dynamic growth environment, with leading economies expanding transplant programs and seeking to integrate advanced antivirals. Regulatory harmonization efforts are under way to expedite approvals, and partnerships between local manufacturers and global innovators aim to address affordability. However, disparities in hospital resources and variations in clinical practice patterns will require tailored strategies to ensure consistent letermovir access across diverse health care settings.

Identifying the Strategies and Collaborative Efforts of Leading Pharmaceutical Companies Driving Innovation and Commercialization of Letermovir Solutions

Merck has established itself as the primary innovator behind letermovir, leveraging extensive clinical trial data and strategic collaborations to underpin its market leadership. The company’s engagement with transplant consortiums and key opinion leaders has fostered widespread guideline endorsements and solidified its reputation in CMV prophylaxis. In parallel, generic producers are preparing to enter selected markets with bioequivalent formulations once exclusivity periods lapse, aiming to drive broader access through competitive pricing.

Biotech partnerships are emerging to explore combination regimens and novel delivery technologies, with some players investigating long-acting injectable formulations to minimize dosing frequency. Licensing agreements between global pharmaceutical firms and regional distributors have expedited availability in markets with complex regulatory requirements. In addition, strategic acquisitions and joint ventures focused on emerging antiviral mechanisms suggest that the broader oncology and transplant support landscape may witness further consolidation and expanded therapeutic portfolios.

Proposing Actionable Recommendations for Industry Stakeholders to Enhance Access Optimize Treatment Protocols and Ensure Sustainable Letermovir Deployment

Industry stakeholders should deepen collaboration with transplant centers to generate robust real-world evidence, demonstrating clinical and economic benefits of sustained prophylaxis. Pharmaceutical manufacturers can invest in patient support programs that address adherence barriers, leveraging telehealth platforms for remote monitoring and educational outreach. Supply-chain resilience must be strengthened by diversifying API sourcing and establishing regional distribution hubs to mitigate tariff and logistical disruptions.

Regulatory teams are encouraged to pursue accelerated approval pathways in emerging markets, aligning dossier submissions with harmonized guidelines and engaging health authorities early to streamline review processes. Payers and policy makers should be engaged through value-based agreements that reflect the long-term reductions in CMV-related complications and hospital readmissions. Finally, cross-sector alliances involving payers, providers, and patient advocacy groups can foster comprehensive care models, ensuring that letermovir reaches all eligible transplant recipients with timely and consistent access.

Outlining Robust Mixed Method Research Methodology Employed to Gather Primary and Secondary Data Insights on Letermovir Market and Clinical Utilization Trends

The research methodology underpinning this analysis integrates both qualitative and quantitative techniques to ensure rigorous and balanced findings. Primary research included structured interviews with transplant physicians, infectious disease experts, hospital pharmacists, and procurement specialists across key regions. These conversations provided direct insights into clinical decision-making processes, formulary considerations, and patient management challenges.

Secondary research entailed systematic review of peer-reviewed literature, regulatory filings, and publicly available treatment guidelines, as well as analysis of company press releases and corporate presentations. Where applicable, tariff schedules and trade publications were examined to quantify policy shifts and supply-chain impacts. Data triangulation techniques were employed to cross-validate insights from multiple sources, enhancing reliability. Internal expert reviews and methodological audits further reinforced the analytical framework, ensuring that conclusions and recommendations accurately reflect the current market and clinical environment.

Synthesizing Key Findings and Strategic Imperatives from Comprehensive Analysis of Letermovir Landscape to Inform Future Research and Policy Directions

This comprehensive analysis illuminates the critical role of letermovir in advancing CMV prophylaxis for transplant recipients, synthesizing the latest clinical insights, policy developments, and market dynamics. Technological innovations and practice shifts have collectively enhanced patient pathways, while tariff changes underscore the importance of supply-chain agility. Segmentation findings reveal nuanced patterns of utilization across indications, administration routes, distribution channels, and end users, informing targeted engagement strategies.

Regional evaluations highlight varying adoption trajectories, with mature markets demonstrating rapid integration and emerging regions poised for growth amid regulatory reforms. Leading pharmaceutical companies are refining commercialization approaches through partnerships, generics preparedness, and R&D collaborations. The actionable recommendations presented herein offer a strategic blueprint for stakeholders to optimize access, support evidence generation, and sustain long-term value creation. By adopting these imperatives, decision-makers can navigate complexities and drive improved outcomes for vulnerable transplant populations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Hematopoietic Stem Cell Transplantation
      • Allogeneic
      • Autologous
    • Solid Organ Transplantation
      • Kidney
      • Liver
  • Route Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Ambulatory Care Centers
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • AiCuris Anti-infective Cures GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Vi at ris Inc.
  • Dr. Reddy’s Laboratories Limited
  • Sandoz International GmbH
  • Natco Pharma Limited
  • Hikma Pharmaceuticals plc
  • Apotex Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of letermovir prophylaxis to solid organ transplant recipients to prevent CMV reactivation
5.2. Real-world evidence studies assessing long-term safety and efficacy of letermovir in HSCT patients
5.3. Pharmacoeconomic analyses highlighting cost-effectiveness of letermovir versus standard CMV therapies in different regions
5.4. Development of novel intravenous and subcutaneous formulations of letermovir for improved patient compliance
5.5. Impact of emerging generic anti-CMV agents on the pricing strategy and market share of branded letermovir
5.6. Integration of therapeutic drug monitoring and pharmacogenetic profiling to optimize personalized letermovir dosing regimens
5.7. Pediatric clinical trials exploring safety and dosing of letermovir for congenital or pediatric CMV prophylaxis in transplant settings
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Letermovir Drugs Market, by Indication
8.1. Introduction
8.2. Hematopoietic Stem Cell Transplantation
8.2.1. Allogeneic
8.2.2. Autologous
8.3. Solid Organ Transplantation
8.3.1. Kidney
8.3.2. Liver
9. Letermovir Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Letermovir Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Letermovir Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Letermovir Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Letermovir Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Letermovir Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Gilead Sciences, Inc.
15.3.3. AiCuris Anti-infective Cures GmbH
15.3.4. Teva Pharmaceutical Industries Ltd.
15.3.5. Vi at ris Inc.
15.3.6. Dr. Reddy’s Laboratories Limited
15.3.7. Sandoz International GmbH
15.3.8. Natco Pharma Limited
15.3.9. Hikma Pharmaceuticals plc
15.3.10. Apotex Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LETERMOVIR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LETERMOVIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. LETERMOVIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. LETERMOVIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. LETERMOVIR DRUGS MARKET: RESEARCHAI
FIGURE 24. LETERMOVIR DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 25. LETERMOVIR DRUGS MARKET: RESEARCHCONTACTS
FIGURE 26. LETERMOVIR DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LETERMOVIR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LETERMOVIR DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LETERMOVIR DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY LIVER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LETERMOVIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES LETERMOVIR DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 77. CANADA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. CANADA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. CANADA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. CANADA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. CANADA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. CANADA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. CANADA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. CANADA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 92. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 93. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. MEXICO LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA LETERMOVIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 154. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 155. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. GERMANY LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 166. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 167. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. FRANCE LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. ITALY LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. ITALY LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. ITALY LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 190. ITALY LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 191. ITALY LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. ITALY LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. ITALY LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. ITALY LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ITALY LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ITALY LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 202. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 203. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SPAIN LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 250. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 251. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. DENMARK LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. QATAR LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. QATAR LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. QATAR LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 274. QATAR LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 275. QATAR LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. QATAR LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. QATAR LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. QATAR LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. QATAR LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. QATAR LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 286. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 287. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 288. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 289. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. FINLAND LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 298. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 299. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 300. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 310. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 311. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 312. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA LETERMOVIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 322. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 323. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2018-2024 (USD MILLION)
TABLE 324. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, 2025-2030 (USD MILLION)
TABLE 325. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. EGYPT LETERMOVIR DRUGS MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Letermovir Drugs market report include:
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • AiCuris Anti-infective Cures GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Vi at ris Inc.
  • Dr. Reddy’s Laboratories Limited
  • Sandoz International GmbH
  • Natco Pharma Limited
  • Hikma Pharmaceuticals plc
  • Apotex Inc.

Related Reports

Letermovir Tablets Market by Route of Administration (Intravenous, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User, Patient Age Group, Dosage Strength - Global Forecast 2025-2030 - Product Image

Letermovir Tablets Market by Route of Administration (Intravenous, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User, Patient Age Group, Dosage Strength - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Cytomegalovirus Treatment Drugs Market by Drug Type (Nucleoside Analogues, Terminase Inhibitors), Route Of Administration (Intravenous, Oral), End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cytomegalovirus Treatment Drugs Market by Drug Type (Nucleoside Analogues, Terminase Inhibitors), Route Of Administration (Intravenous, Oral), End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
T-Cell Prolymphocytic Leukemia (T-PLL) - Pipeline Insight, 2025 - Product Image

T-Cell Prolymphocytic Leukemia (T-PLL) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Trends in Antiviral Drug Development. Edition No. 1. Trends in Drug Discovery - Product Image

Trends in Antiviral Drug Development. Edition No. 1. Trends in Drug Discovery

  • Book
  • 528 Pages
Current Trends in the Identification and Development of Antimicrobial Agents - Product Image

Current Trends in the Identification and Development of Antimicrobial Agents

  • Book
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.